Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 650.11K | 959.42K | 615.57K | 816.01K | 696.27K | 702.16K |
| Gross Profit | -691.43K | -924.12K | -1.12M | -1.53M | -1.90M | -397.67K |
| EBITDA | -13.23M | -15.55M | -21.87M | -16.47M | -19.57M | -11.43M |
| Net Income | -29.41M | -29.69M | -22.63M | -17.53M | -20.56M | -13.08M |
Balance Sheet | ||||||
| Total Assets | 55.57M | 21.62M | 8.31M | 13.70M | 26.86M | 33.57M |
| Cash, Cash Equivalents and Short-Term Investments | 50.34M | 15.71M | 831.52K | 5.69M | 18.52M | 25.14M |
| Total Debt | 24.81M | 21.35M | 10.42M | 4.45M | 1.74M | 1.39M |
| Total Liabilities | 32.49M | 29.00M | 17.06M | 6.19M | 4.46M | 4.75M |
| Stockholders Equity | 23.08M | -7.38M | -12.83M | 7.51M | 22.40M | 28.82M |
Cash Flow | ||||||
| Free Cash Flow | -12.27M | -15.65M | -13.06M | -17.06M | -18.11M | -12.97M |
| Operating Cash Flow | -12.12M | -15.57M | -12.98M | -16.82M | -17.49M | -12.23M |
| Investing Cash Flow | -157.60K | -74.98K | -82.78K | -238.86K | -695.30K | -774.03K |
| Financing Cash Flow | 32.21M | 30.33M | 8.21M | 3.94M | 11.59M | 33.02M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$634.48M | -9.17 | -432.03% | ― | -8.99% | -18.16% | |
47 Neutral | $46.89M | -2.00 | -74.00% | ― | 23.31% | -17.35% | |
46 Neutral | AU$130.03M | -9.69 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$164.50M | -15.43 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$46.02M | -8.27 | -513.22% | ― | -34.06% | 75.47% | |
41 Neutral | AU$63.89M | -3.89 | -128.19% | ― | -14.25% | -22.83% |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Medical Systems has secured U.S. FDA 510(k) clearance for its NorthStar Mapping System, the first and only MRI-native 3D mapping and guidance platform to receive such approval, marking its first capital equipment and software-centric product cleared in the U.S. market. The clearance allows commercial launch of NorthStar in the world’s largest electrophysiology market and positions the system as the foundational software hub for interventional cardiac MRI labs, underpinning Imricor’s full MRI-guided electrophysiology platform and opening a new, AI-enabled software era for the company with substantial implications for future product expansion and market growth.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems reported its fourth-quarter 2025 activities, highlighting a series of clinical and technological milestones that advance real-time MRI-guided cardiac ablation toward broader global adoption. The company announced the world’s first ischemic ventricular tachycardia ablation and the first preclinical pulsed field ablation in the ventricle under real-time MRI guidance, expansion of its VISABL-AFL and VISABL-VT clinical trial programs with new U.S. and European hospital sites, and completed integration of its NorthStar system with Philips scanners, paving the way for site conversions in Europe and the Middle East while continuing integration work with General Electric ahead of a U.S. launch. Commercial momentum included a strengthened board with a former Johnson & Johnson MedTech executive, growing pipeline exceeding 40 sites, new iCMR lab construction and strong physician interest in Saudi Arabia, and heightened public visibility via television coverage. Financially, Imricor recorded operating cash outflows of US$5.2 million and minimal customer receipts in the quarter, reflecting the temporary revenue impact of enrolling hospitals in non-revenue-generating clinical trials, while ending 2025 with US$19.5 million in cash and US$21.3 million in short-term investments, positioning the company to fund its regulatory, clinical, and commercial execution as it seeks to solidify its role in redefining complex arrhythmia treatment without reliance on x-ray.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has secured Institutional Review Board approval for Virginia Commonwealth University Health to join its VISABL-AFL clinical trial, making VCU Health the third U.S. site participating in the study supporting U.S. FDA approval of Imricor’s cardiac ablation products. With budgeting, installation and training expected to conclude in February and procedures slated to begin in March under Principal Investigator Dr Ajay Pillai, the addition of a large, nationally ranked academic health system underscores growing clinical interest in Imricor’s MRI‑guided NorthStar mapping system and Vision-MR mapping and ablation catheters, and marks a further step in advancing its U.S. regulatory and commercial positioning in cardiac ablation.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems Inc., an ASX-listed medical technology company focused on cardiac-related products, maintains its issued capital structure through various classes of securities, including options listed under the code IMRAJ. The company has notified the market that 52,500 IMRAJ options, which were subject to various exercise prices and expiry dates, have lapsed effective 1 January 2026 because the conditions for exercising these rights were not met or had become incapable of being satisfied, resulting in a modest reduction in potential future dilution for existing shareholders and a slight simplification of the company’s capital structure.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has notified the market of the issue of 155,000 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 1 January 2026. The new options, which will not be quoted on the ASX, form part of the company’s broader strategy to align staff incentives with shareholder interests and support retention and motivation of key employees as it advances its medical technology portfolio.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has received its first-ever clearance from the US Food and Drug Administration for the Vision-MR Diagnostic Catheter, an MRI-guided electrophysiology device that forms a key element of its MRI-compatible EP platform. The 510(k) clearance allows Imricor to begin commercially marketing the catheter in the United States, the world’s largest electrophysiology market, marking a significant milestone in its US market entry and setting the stage for additional regulatory clearances as the company rolls out its full MRI-guided EP portfolio, with potentially meaningful implications for its growth trajectory and competitive positioning in advanced cardiac ablation technologies.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has announced that Charité University Hospital in Berlin, one of the world’s leading hospitals, will become the second site globally to join the company’s VISABL-VT clinical trial, which is aimed at advancing real-time MRI-guided ablation for ventricular tachycardia. Following software upgrades to Charité’s Philips MRI system to integrate Imricor’s NorthStar mapping platform and the removal of now-commercial CE-marked Imricor devices from the investigational study framework, the trial protocol has been simplified, and Charité’s electrophysiology team plans to begin commercial atrial flutter ablations in the MRI lab from the first quarter of 2026, underscoring Imricor’s strengthening clinical footprint and its strategic collaboration with Philips in MRI-guided electrophysiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has announced that the University of Virginia Health Medical Center will become the second US site for its VISABL-AFL clinical trial, following IRB approval. This development marks a significant step in Imricor’s efforts to enhance MRI-guided electrophysiology ablations, with procedures expected to begin in February. The expansion to UVA Health is part of a broader strategy to ensure timely enrolment and FDA processes, positioning Imricor to strengthen its market presence and impact in the field of interventional cardiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. announced a significant milestone in the field of MRI-guided electrophysiology with the successful completion of the first ischemic ventricular tachycardia (VT) ablation performed entirely under real-time MRI guidance. This groundbreaking procedure, conducted at Amsterdam University Medical Centre, marks a critical advancement in treating complex arrhythmias and demonstrates the potential for safer and more effective ablations, even in high-risk patients with implantable cardioverter defibrillators. The achievement is expected to drive increased demand for Imricor’s technology and accelerate its adoption across Europe, as additional sites are set to join the VISABL-VT clinical trial.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.